Demographic details of a cohort of 788 HIV-infected patients with and without metabolic syndrome by IDF and ATPIII criteria
| Characteristic | IDF | ATPIII | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | No metabolic syndrome | P value | Metabolic syndrome | No metabolic syndrome | P value | |||||
| n | 114 | 674 | 139 | 649 | ||||||
| Male | 83 (73) | 580 (86) | 0.0003 | 118 (85) | 545 (79) | |||||
| Age (years) | 45 ± 10 | 41 ± 9 | <0.0001 | 46 (9) | 41 (9) | <0.0001 | ||||
| BMI (kg/m2) | 27 ± 4 | 23 ± 3 | <0.0001 | 26 (5) | 23 (3) | <0.0001 | ||||
| Systolic BP (mmHg) | 130 ± 15 | 122 ± 15 | <0.0001 | 134 ± 16 | 121 ± 14 | <0.0001 | ||||
| Diastolic BP (mmHg) | 81 ± 10 | 76 ± 10 | 0.23 | 81 ± 10 | 75 ± 10 | <0.0001 | ||||
| HIV duration (years) | 8.1 ± 4.0 | 7.8 ± 5.0 | 0.05 | 9.0 (4) | 7.5 (5) | 0.01 | ||||
| Lipodystrophy cases | 83 (73) | 368 (55) | 0.31 | 110 (79) | 341 (53) | <0.001 | ||||
| CDC categories | 0.05 | |||||||||
| Category A | 59 (52) | 338 (50) | 60 (43) | 337 (52) | ||||||
| Category B | 31 (27) | 153 (23) | 31 (22) | 153 (24) | ||||||
| Category C | 24 (21) | 184 (27) | 48 (35) | 159 (24) | ||||||
| Current drug therapies | ||||||||||
| NRTI | 102 (89) | 572 (86) | 0.3 | 124 (89) | 550 (86) | 0.29 | ||||
| Lamivudine | 82 (72) | 417 (63) | 92 (66) | 409 (64) | ||||||
| Zidovudine | 37 (32) | 217 (33) | 45 (32) | 209 (33) | ||||||
| Stavudine | 55 (48) | 266 (40) | 63 (45) | 258 (40) | ||||||
| Abacavir | 85 (21) | 47 (23) | 29 (21) | 103 (16) | ||||||
| Didanosine | 13 (11) | 129 (19) | 23 (17) | 119 (19) | ||||||
| NNRTI | 41 (36) | 258 (39) | 0.57 | 49 (35) | 250 (39) | 0.41 | ||||
| Nevirapine | 17 (15) | 116 (17) | 18 (13) | 115 (18) | ||||||
| Efavirenz | 23 (20) | 134 (20) | 30 (22) | 127 (20) | ||||||
| Delaviridine | 1 (1) | 10 (2) | 1 (<1) | 10 (2) | ||||||
| Protease inhibitors | 68 (60) | 329 (49) | 0.04 | 82 (59) | 315 (49) | 0.04 | ||||
| Indinavir | 28 (25) | 91 (14) | 30 (22) | 89 (14) | ||||||
| Nelfinavir | 21 (18) | 95 (14) | 18 (13) | 98 (15) | ||||||
| Saquinavir hard gel | 7 (6) | 31 (5) | 10 (7) | 28 (4) | ||||||
| Saquinavir soft gel | 2 (2) | 49 (7) | 8 (6) | 43 (6) | ||||||
| Ritonavir <400 mg/day | 16 (14) | 99 (15) | 30 (22) | 85 (13) | ||||||
| Ritonavir >400 mg/day | 9 (8) | 49 (7) | 16 (12) | 42 (7) | ||||||
| Lopinavir/ritonavir | 9 (8) | 63 (9) | 16 (12) | 56 (9) | ||||||
| Amprenavir | 4 (4) | 27 (4) | 6 (4) | 25 (4) | ||||||
| Alcoholic beverages* | ||||||||||
| <7 | 98 (86) | 519 (7) | 0.16 | 122 (88) | 495 (77) | 0.007 | ||||
| 7–13 | 11 (10) | 96 (14) | 15 (11) | 92 (14) | ||||||
| >14 | 5 (4) | 49 (7) | 2 (1) | 52 (8) | ||||||
| Physical activity | ||||||||||
| Sedentary | 35 (31) | 204 (31) | 0.12 | 47 (34) | 495 (77) | 0.19 | ||||
| Low | 40 (35) | 167 (25) | 35 (25) | 172 (27) | ||||||
| Moderate | 26 (23) | 192 (29) | 44 (32) | 174 (27) | ||||||
| High | 13 (11) | 101 (15) | 13 (9) | 101 (16) | ||||||
| Dietary intent | ||||||||||
| Increase weight | 22 (11) | 133 (20) | 0.008 | 28 (20) | 117 (18) | 0.11 | ||||
| Maintain weight | 81 (71) | 461 (69) | 88 (63) | 454 (71) | ||||||
| Decrease weight | 21 (18) | 71 (11) | 23 (17) | 69 (11) | ||||||
Data are means ± SD or n (%).
↵* Standard drinks consumed each week. P values are for t test comparisons for antiretroviral drug use in those with and without metabolic syndrome. BP, blood pressure; CDC, Centers for Disease Control and Prevention; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors.